Objective
* To produce a genetically detoxified H. pylori cytotoxin protein suitable for evaluation as a vaccine candidate.
* To assess the genetic variability of Chinese isolates of H. pylori, and to evaluate the relationship of this variability to the incidence of severe disease.
* To test in the mouse model, vaccine candidates which show promise in protecting against European strains of H. pylori for their capacity to induce protection against infection by virulent Chinese strains.
Expected Outcome
* Identification of biologically relevant regions of the VacA protein.
* A genetically detoxified and antigenically intact cytotoxin molecule as a vaccine candidate.
* Serological data on the association of infection with Type I, VacA and CagA expressing strains with gastroduodenal disease in China.
* Genotypic and phenotypic data on the variation of H. pylori strains in clinical isolates form Chinese patients and their assocation with disease.
* Pathogenicity in vivo and in vitro of clinical isolates from China related to their genotype and phenotype.
* Evaluation of the cytotoxin toxoids in conferring protective immunity against infection by European and Chinese strains of H. pylori.
* A bank of monclonal antibodies raised against purified native toxin wil be screened for their ability to neutralize purified toxin.
* Sequences coding for potentially non-toxic VacA proteins willl be created in
E. coli by site directed mutagensis.
Mutated genes constructed in E. coli will be transferred into H. pylori.
* Mutated toxin proteins will be tested for their ability to induce gastric lesions after oral administration to mice.
* Sera from Chinese patients undergoing routine endoscopy will be analysed for their ability to recognize CagA, VacA and other H. pylori antigens to ascertain any correlation with particular conditions such as duodenal ulcer and gastric cancer.
* Strains isolated by endoscopy from Chinese patients will be analysed for the presence of the CagA genotype and by immunoblot for expression of CagA and VacA proteins.
* Selected isolated of different genotype and phenotype will be adapted to mice by sequential passage.
* Non-toxic VacA proteins will be tested for their ability to protect mice from infection with European and Chinese strains of H. pylori adapted to colonization of mice.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
53100 SIENA
Italy
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.